Public funding and pricing
The Norwegian Medical Products Agency is responsible for assessing the cost-effectivness of and setting maximum prices for prescription-only-medicines.
Strengthening the System for the Assessment of Medical Devices in the specialist health care services
Published:
FINOSE becomes Joint Nordic HTA-Bodies, JNHB
Published:
Switching between a reference product and a biosimilar
Published:
|
Updated:
Closer Nordic co-operation regarding more paediatric medicines
Published:
|
Updated: